Last reviewed · How we verify

Transdermal strogen — Competitive Intelligence Brief

Transdermal strogen (Transdermal strogen) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy (HRT) / Estrogen replacement. Area: Endocrinology / Women's Health.

marketed Hormone replacement therapy (HRT) / Estrogen replacement Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Endocrinology / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Transdermal strogen (Transdermal strogen) — Parc de Salut Mar. Transdermal estrogen delivers estradiol through the skin to replace or supplement endogenous estrogen levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Transdermal strogen TARGET Transdermal strogen Parc de Salut Mar marketed Hormone replacement therapy (HRT) / Estrogen replacement Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy (HRT) / Estrogen replacement class)

  1. Parc de Salut Mar · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Transdermal strogen — Competitive Intelligence Brief. https://druglandscape.com/ci/transdermal-strogen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: